This is the authors' abstract. We don't add key points for this paper.
Combination treatments with agents that inhibit protease and reverse transcriptase of human immunodeficiency virus type 1 (HIV-1) decrease mortality and slow disease progression.1 The development of resistance to these drugs, however, limits the benefit of such treatments.2,3 There have been reports of the transmission of HIV-1 variants that are resistant to nucleoside and non-nucleoside inhibitors of reverse transcriptase.4–9 The transmission of HIV-1 variants that are resistant to protease inhibitors could represent an important emerging clinical and public health problem. We report a case of transmission of an HIV-1 variant with multiple mutations that conferred resistance to both protease . . .
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Hecht et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: